STX-241 FIH (F60087CI101)

RMC-LUNG-101A

RMC-LUNG-101

LB100

RMC-6291-101

STX-721-101

StrateGIST 1 (IDRX-42-001)

D6900C00001

CA1201001

M22TGA

CTLR-101

IMC-F106C-101 (PRAME)

TCD17620

MCLA-129-CL01

D9570C00001

GO43860

XL092-001

SGNPDL1V-001

INCB 123667-101

PROACTIVE

1479-0001

CyPep-1

VHIO17002

MCLA-128-CL01

KEYNOTE 158

DESTINY-Lung03

A Phase I/IIa Multi-center, Open-label Master Protocol to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Antitumor Activity of&nbsp;AZD8205&nbsp;in Participants With Advanced or Metastatic Solid Malignancies.



<ul class="wp-block-list">
<li>Code NKI: M23ABD</li>



<li>Code firma: D6900C00001</li>



<li>Code clinicaltrials.gov: NCT05123482</li>
</ul>



Principal Investigator



Dr. M. van Dongen



Drugs 



B7-H4 ADC monotherapy



<ul class="wp-block-list">
<li>Mammary carcinoma, endometrial carcinoma &#8211; open (not for TNBC)</li>



<li>Cholangiocarcinoma, TNBC &#8211; closed</li>
</ul>



<h2 class="wp-block-heading">Summary</h2>



This research study is studying a new compound,&nbsp;AZD8205, as a possible treatment for advanced or metastatic solid tumours.



Read more on <a href="https://clinicaltrials.gov/study/NCT05123482?term=AZD8205&amp;rank=1#study-overview" data-type="URL" data-id="https://www.clinicaltrials.gov/study/NCT04868877?term=MCLA-129-CL01&amp;rank=1">clinicaltrials.gov</a>